+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Israel Cancer Research Fund Project Grants

Israel Cancer Research Fund

Israel Cancer Research Fund (ICRF) Project Grants provide funding for projects of high scientific merit and clear potential significance for advancing the understanding, diagnosis, or treatment of cancer. Project Grants are intended to support the research of established investigators working in areas in which they have demonstrated expertise.

Duration and Amount of Funding

Project Grants are awarded for three (3) years for $60,000 per year, as determined by the International Board of Trustees and availability of funds. Funding for the second and third years is contingent on progress in the preceding funding period, as documented in a Progress Report due annually on June 30.

AI Based Application Success Predictor

1. Strong, Direct Relevance to Cancer Research

ICRF supports all areas of cancer research (basic → translational → clinical), but successful proposals have a clear cancer-specific rationale, such as:

Cancer genetics and epigenetics

Tumor immunology & immunotherapy

Tumor microenvironment

Drug discovery & targeted therapy

Early detection and biomarkers

Cancer metabolism

Computational/AI cancer biology

Tumor heterogeneity & resistance

Metastasis mechanisms

Predictor: Your proposal must explicitly advance understanding of cancer mechanisms, detection, or treatment.

2. Strong Fit to ICRF’s Grant Mechanism

ICRF has multiple grant types, each with unique expectations:

🔹 ICRF Research Career Development Award (RCDA)

For early-career faculty in Israel (or Israeli scientists abroad starting jobs in Israel).

Requires strong mentorship, independence plan, and institutional commitment.

🔹 ICRF Project Grants (core mechanism)

1–3 year research projects.

Requires strong preliminary data + feasibility.

🔹 ICRF Acceleration Grants

High-risk, high-impact, innovative work with transformative potential.

🔹 ICRF–AACR Partner Awards / Thematic Calls

Highly specific cancer areas, often translational.

🔹 ICRF–U.S. Partnerships (e.g., ICRF–Chicago, ICRF–Toronto)

May include priority disease areas.

Predictor: Match career stage, institution, and project type to the correct grant.

3. Strong Preliminary Data

Even for “acceleration” or early-career awards, competitive proposals include:

Pilot data supporting feasibility

Validation of methods or models

Early signals supporting the hypothesis

Demonstration that required datasets/materials are available

Predictor: ICRF rarely funds projects that lack preliminary evidence.

4. Innovation + High Scientific Impact

ICRF reviewers favor projects that:

Push boundaries (not incremental)

Introduce new tools, paradigms, or therapeutic strategies

Offer clear translational or mechanistic advances

Could lead to major discoveries in cancer biology or treatment

Address unmet medical needs or hard-to-treat cancers

Predictor: Innovation + potential to meaningfully impact cancer care or science.

5. Strong Research Track Record (Especially for Project Grants)

Funded investigators typically demonstrate:

High-quality recent publications

Productivity in the proposed field

Ability to execute similar research

Successful mentorship and collaborations

Predictor: A strong publication record closely aligned with the proposed topic.

6. Excellence of Host Institution (Israel-Based)

ICRF funds research conducted in Israel only (with rare joint exceptions). Strong proposals show:

Access to relevant research infrastructure (omics, imaging, bioinformatics, PDXs, patient samples)

Strong departmental and institutional support

Commitment of lab space, resources, core facilities

Predictor: Being at a leading Israeli research center with appropriate facilities strongly boosts competitiveness.

7. Clear, Feasible, Milestone-Driven Specific Aims

Strong ICRF proposals include:

2–3 focused Aims

Clear hypotheses, endpoints, and methods

Feasible 1–3 year execution timeline

Go/no-go milestones

Risk mitigation strategies

Predictor: Realistic, tightly structured projects score much higher.

8. Collaboration & Interdisciplinary Strength

ICRF values Israeli scientific collaboration—especially cross-institutional or cross-disciplinary partnerships.

Strong proposals often include:

Joint Israeli–international collaborations

Multi-PI synergy (e.g., computational + wet-lab + clinical)

Co-mentorship for early-career applicants

Predictor: Collaborative value improves competitiveness.

9. Clear Writing, Logic, and Presentation

Successful ICRF grant applications are:

Very clearly written

Well organized (NIH-like structure)

Supported by strong figures for preliminary data

Persuasive in rationale and impact

Predictor: Clarity of the proposal has a major effect on reviewer enthusiasm.

10. Alignment With ICRF Mission: “Supporting Cancer Research in Israel”

ICRF has a dual mission:

Advance cancer research

Strengthen Israeli scientific excellence

Applications score higher if they demonstrate:

Training and building capacity in Israel

Contribution to Israeli research leadership

Potential to attract future external funding (NIH, ERC, etc.)

Predictor: Explicitly showing how your work strengthens Israel’s cancer research ecosystem.

🏆 Summary Table — ICRF Success Predictors

Predictor	Why It Matters
Cancer-specific focus	Core eligibility
Correct mechanism alignment	Ensures proper scope & expectations
Strong preliminary data	Demonstrates feasibility
Innovation + high impact	Central ICRF priority
Strong publication track record	Predictor of successful outcomes
Strong Israeli institutional support	Required for infrastructure and execution
Collaborative value	Enhances impact
Feasible aims & timeline	Supports high reviewer confidence
Clear, persuasive writing	Improves scores
Contribution to Israeli cancer research	Aligns with ICRF mission

Specialties

Cancer

Oncology

Eligibility Requirements

The applicant must be an independent investigator who has demonstrated ability to lead a research team, as evident in the Biosketch and Publication Record. Applications must focus on questions related to human cancer that are supported by strong published or preliminary data and provide a solid foundation for future progress. Funding priority is typically given to projects with potential to impact prevention, diagnosis, or treatment of cancer in the next 5-10 years. Interdisciplinary approaches are encouraged, but not required.

The Principal Investigator (PI) must be an established independent researcher who has demonstrated ability to lead a research team, as evident in the Biosketch and Publication Record. The PI is responsible for the scientific direction, integrity, and conduct of the research, including the study design, data management, and timely reporting. Additional Co-Investigators may be named, but it is the PI who is ultimately responsible for all aspects of the research, and all communication with ICRF is to be conducted solely via the PI.

Eligible Countries:

Israel

Sponsor Details

Sponsor Institute/Organizations: Israel Cancer Research Fund

Sponsor Type: Corporate/Non-Profit

Address: 52 Vanderbilt Avenue, Suite 1410 New York, New York 10017-3835

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity